2AMGN : Amgen's Options: A Look at What the Big Money is Thinking
The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...
Fierce Pharma4d
Trial results enhance Bristol Myers' bid for Sotyktu in psoriatic arthritis
Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What is William Blair’s Forecast for Amgen Q4 Earnings?
Investment analysts at William Blair issued their Q4 2026 earnings per share estimates for Amgen in a research report issued ...
Q1 Earnings Forecast for Amgen Issued By William Blair
Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Amgen in a research note issued on ...
Amgen And Kyowa Kirin Provide Top-line Results From Rocatinlimab Phase 3 Ignite Study In Adults With Moderate To Severe Atopic Dermatitis
Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa ...
Bristol Myers says over 50% responded to Sotyktu in psoriatic arthritis trial
Bristol-Myers Squibb (BMY) stock in focus as psoriasis drug Sotyktu shows promising results in treating psoriatic arthritis ...
How a skin drug trial could help Peninsula biotech pull off key merger
Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
pharmaphorum3d
BMS scores first approval for psoriasis therapy Sotyktu
BMS has set a list price of $6,164 for a 30-day supply of the new drug, which is around 42% higher than the $4,344 Amgen charges wholesalers for a 30-day supply of Otezla, ahead of any discounts ...